Scholay

学术搜索 · AI 审稿 · LaTeX 协作

Songwen Zhou

机构：Tianjin Medical University Cancer Institute and Hospital · ORCID：0000-0002-9377-320X

发表论文 16 篇 · 总被引 5152 次 · h-index 10

代表论文

  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study (2011 · The Lancet Oncology · 被引 4117)
  • Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) (2015 · Annals of Oncology · 被引 468)
  • MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer (2013 · Lung Cancer · 被引 178)
  • Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) (2013 · Annals of Oncology · 被引 121)
  • Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). (2012 · Journal of Clinical Oncology · 被引 79)
  • Predictive Effects of ERCC1 and XRCC3 SNP on Efficacy of Platinum-based Chemotherapy in Advanced NSCLC Patients (2010 · Japanese Journal of Clinical Oncology · 被引 53)